Citations

Clear

4802 citation(s) found for "Yu, Jennifer".

CTNI-05. PRELIMINARY RESULTS OF THE NERATINIB ARM IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II PLATFORM TRIAL USING BAYESIAN ADAPTIVE RANDOMIZATION
Arrillaga‐Romany, Isabel , Trippa, Lorenzo , Fell, Geffrey, Lee, Eudocia Q. , Rahman, Rifaquat , McCluskey, Christine , Gaffey, Sarah, Lassman, Andrew B. , Ahluwalia, Manmeet S. , Colman, Howard , Hepel, Jaroslaw T., Elinzano, Heinrich, Schiff, David , Chukwueke, Ugonma , Nayak, Lakshmi , Batchelor, Tracy T. , Lu‐Emerson, Christine , Haas‐Kogan, Daphne A. , Cagney, Daniel , Aizer, Ayal A. , Welch, Mary , Doherty, Lisa, Lavallee, Maria, Fisher-Longden, Brittany, Dowling, Shanna, Watkinson, Fiona , Reardon, David A. , Wen, Patrick Y. , Ahluwalia, Manmeet S , Arrillaga‐Romany, Isabel , Touat, Mehdi , Bruno, Jennifer, Drappatz, Jan , Galanis, Evanthia , Colman, Howard , Nabors, Burt , Kaley, Thomas , Mellinghoff, Ingo K. , Beroukhim, Rameen , McFaline-Figueroa, J Ricardo , Bi, Wenya Linda , Arnaout, Omar M. , Peruzzi, Pier Paolo , Tanguturi, Shyam K , Geduldig, Jack , Santagata, Sandro , Meredith, David M. , Chiocca, E Antonio , Ligon, Keith L , Alexander, Brian M. , Wen, Patrick Yung

Mayo Clinic

Neuro-Oncology | November 18, 2021 | Volume: 23 | Issue: Supplement_6 | Pages: vi59-vi59

10.1093/neuonc/noab196.230 Get It

Abstract BACKGROUND EGFR is amplified in over 50% of glioblastoma and 20-30% have EGFRvIII mutations. Neratinib is a potent inhibitor of EGFR/HER2 approved for metastatic HER2+ breast cancer. To efficiently evaluate the potential impact of neratinib on overall survival (OS) in newly-diagnosed glioblastoma and to simultaneously develop information regarding potential genomic biomarker associations, neratinib was included as an arm on the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) trial. INSIGhT is a phase II platform trial using response adaptive randomization and deep genomic profiling to more efficiently test experimental agents in MGMT unmethylated glioblastoma and accelerate identification of novel therapies for phase III testing. Initial randomization was equal between neratinib, control, and two other experimental arms but subsequent randomization was adapted based on efficacy as determined by progression-free survival (PFS). We report preliminary results for the neratinib arm. METHODS Patients with newly diagnosed MGMT-unmethylated glioblastoma were randomized to receive either radiotherapy with concomitant and adjuvant temozolomide or standard radiochemotherapy followed by adjuvant neratinib (240 mg daily). Treatment continued until progression or development of unacceptable toxicities. The primary endpoint was OS. Association between neratinib efficacy and EGFR amplification was also investigated. RESULTS There were 144 patients (70 control; 74 neratinib). Neratinib was reasonably well-tolerated with no new toxicity signals identified. PFS was compared (HR 0.84; p=0.38, logrank test – not significant) between the neratinib (median 6.05 months) and control (median 5.82 months) arms. For patients EGFR pathway activation the PFS HR was 0.53 (p-value=0.03 – significant, median PFS: neratinib, 6.21 months, control, 5.26 months). However, there was no significant improvement in OS in EGFR amplified/mutated patients (HR 1.05; p-value 0.87) between neratinib (median 14.2) compared to the control arm (median 14.6). CONCLUSION Neratinib prolonged PFS in the EGFR positive subpopulation but there was no overall PFS benefit, or any OS improvement.
A Description of COVID-19-Directed Therapy in Children Admitted to US Intensive Care Units 2020
Schuster, Jennifer E. , Halasa, Natasha , Nakamura, Mari , Levy, Emily R. , Young, Cameron C. , Newhams, Margaret M. , Bourgeois, Florence T. , Staat, Mary Allen , Hobbs, Charlotte V. , Feldstein, Leora R. , Jackson, A. , Mack, Elizabeth H. , Walker, Tracie C. , Spinella, Philip C. , Loftis, Laura L. , Kong, Michele , Rowan, Courtney M. , McLaughlin, Gwenn E., Hall, Mark W. , Babbitt, Christopher , Maamari, Mia , Zinter, Matt S. , Gertz, Shira J. , Carroll, Christopher L. , Singh, Aalok R. , Hymes, Saul , Schwarz, Adam J. , McGuire, John K. , Nofziger, Ryan A. , Flori, Heidi R. , Clouser, Katharine N. , Wellnitz, Kari , Cullimore, Melissa L. , Hume, Janet R. , Patel, Manish , Randolph, Adrienne G. , Investigators, Overcoming COVID-19, Patel, Manish R. , Feldstein, Leora R , Levy, Emily R , Young, Cameron C , Randolph, Adrienne G , Spinella, Philip C , Kong, Michele , Hume, Janet R , Hobbs, Charlotte V , Staat, Mary A , Gertz, Shira J , Hymes, Saul R , Fitzgerald, Julie C. , Dapul, Heda , Jackson, Ashley M, Maddux, Aline B. , Bembea, Melania M. , Cvijanovich, Natalie Z , Michelson, Kelly Nicole , Thomas, Neal J. , Giuliano, John S. , Investigators, Overcoming COVID-19

Mayo Clinic

Journal of the Pediatric Infectious Diseases Society | November 17, 2021 | Volume: 11 | Issue: 5 | Pages: 191-198

10.1093/jpids/piab123 | PMID 35022779 Get It

Abstract Background It is unclear how acute coronavirus disease 2019 (COVID-19)-directed therapies are used in children with life-threatening COVID-19 in US hospitals. We described characteristics of children hospitalized in the intensive care unit or step-down unit (ICU/SDU) who received COVID-19-directed therapies and the specific therapies administered. Methods Between March 15, 2020 and December 27, 2020, children <18 years of age in the ICU/SDU with acute COVID-19 at 48 pediatric hospitals in the United States were identified. Demographics, laboratory values, and clinical course were compared in children who did and did not receive COVID-19-directed therapies. Trends in COVID-19-directed therapies over time were evaluated. Results Of 424 children in the ICU/SDU, 235 (55%) received COVID-19-directed therapies. Children who received COVID-19-directed therapies were older than those who did not receive COVID-19-directed therapies (13.3 [5.6-16.2] vs 9.8 [0.65-15.9] years), more had underlying medical conditions (188 [80%] vs 104 [55%]; difference = 25% [95% CI: 16% to 34%]), more received respiratory support (206 [88%] vs 71 [38%]; difference = 50% [95% CI: 34% to 56%]), and more died (8 [3.4%] vs 0). Of the 235 children receiving COVID-19-directed therapies, 172 (73%) received systemic steroids and 150 (64%) received remdesivir, with rising remdesivir use over the study period (14% in March/April to 57% November/December). Conclusion Despite the lack of pediatric data evaluating treatments for COVID-19 in critically ill children, more than half of children requiring intensive or high acuity care received COVID-19-directed therapies.
High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival
Brieger, Katharine K. , Phung, Minh Tung , Mukherjee, Bhramar, Bakulski, Kelly M. , Anton-Culver, Hoda, Bandera, Elisa V. , Bowtell, David D.L., Cramer, Daniel W., DeFazio, Anna , Doherty, Jennifer A. , Fereday, Sian, Fortner, Renée T. , Goode, Ellen L., Goodman, Marc T., Menon, Usha , Moysich, Kirsten B., Qin, Bo , Ramus, Susan J. , Risch, Harvey A., Rossing, Mary Anne, Schildkraut, Joellen M., Trabert, Britton , Wentzensen, Nicolas, Wu, Anna H., Khoja, Lilah , Richardson, Jean , Grout, Bronwyn, Chase, Anne, Deurloo, Cindy McKinnon, Odunsi, Kunle , Brenton, James D. , Terry, Kathryn L., Pharoah, Paul D.P., Berchuck, Andrew, Hanley, Gillian E., Pike, Malcolm C. , Pearce, Celeste Leigh, Goodman, Marc T. , Terry, Kathryn L. , Bowtell, David D.L. , Fereday, Sián , Hanley, Gillian E. , Fortner, Renée T , Gentry‐Maharaj, Aleksandra , Harris, Holly R , Matsuo, Keitaro , Menon, Usha , Modugno, Francesmary , Qin, Bo , Ramus, Susan J , Trabert, B , Vierkant, Robert A , Winham, Stacey J , Ziogas, Argyrios , Khoja, Lilah , Cho, Kathleen R , McLean, Karen , Richardson, Jean , Odunsi, Kunle , Nelson, Brad H , Brenton, James D , Webb, Penelope M , Pike, Malcolm C , Fazio, Anna de , Doherty, Jennifer A , Moysich, Kirsten , Bowtell, David D , Fereday, Sian , Goodman, Marc T , Brieger, Katharine K. , Phung, Minh Tung , Mukherjee, Bhramar, Bakulski, Kelly M. , Anton-Culver, Hoda, Bandera, Elisa V. , Cramer, Daniel W., Goode, Ellen L., Goodman, Marc T., Moysich, Kirsten B. , Risch, Harvey A., Rossing, Mary Anne, Schildkraut, Joellen M., Wentzensen, Nicolas, Wu, Anna H., Grout, Bronwyn, Chase, Anne, Deurloo, Cindy McKinnon, Pharoah, Paul D.P., Berchuck, Andrew, Pearce, Celeste Leigh

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | November 17, 2021 | Volume: 31 | Issue: 2 | Pages: 443-452

10.1158/1055-9965.epi-21-0977 | PMID 34789471 Get It

Abstract Background: There is suggestive evidence that inflammation is related to ovarian cancer survival. However, more research is needed to identify inflammation-related factors that are associated with ovarian cancer survival and to determine their combined effects. Methods: This analysis used pooled data on 8,147 women with invasive epithelial ovarian cancer from the Ovarian Cancer Association Consortium. The prediagnosis inflammation-related exposures of interest included alcohol use; aspirin use; other nonsteroidal anti-inflammatory drug use; body mass index; environmental tobacco smoke exposure; history of pelvic inflammatory disease, polycystic ovarian syndrome, and endometriosis; menopausal hormone therapy use; physical inactivity; smoking status; and talc use. Using Cox proportional hazards models, the relationship between each exposure and survival was assessed in 50% of the data. A weighted inflammation-related risk score (IRRS) was developed, and its association with survival was assessed using Cox proportional hazards models in the remaining 50% of the data. Results: There was a statistically significant trend of increasing risk of death per quartile of the IRRS [HR = 1.09; 95% confidence interval (CI), 1.03–1.14]. Women in the upper quartile of the IRRS had a 31% higher death rate compared with the lowest quartile (95% CI, 1.11–1.54). Conclusions: A higher prediagnosis IRRS was associated with an increased mortality risk after an ovarian cancer diagnosis. Further investigation is warranted to evaluate whether postdiagnosis exposures are also associated with survival. Impact: Given that pre- and postdiagnosis exposures are often correlated and many are modifiable, our study results can ultimately motivate the development of behavioral recommendations to enhance survival among patients with ovarian cancer.
Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What's Past Is Prologue” (Shakespeare)
Mato, Anthony R. , Sharman, Jeff P. , Kay, Neil E. , Kater, Arnon P. , Rogers, Kerry A. , Rhodes, Joanna , Skarbnik, Alan P , Eyre, Toby A. , Nabhan, Chadi , Lamanna, Nicole , Pagel, John M. , Ujjani, Chaitra S. , Brander, Danielle M. , Coombs, Catherine C. , Cheah, Chan Y. , Brown, Jennifer R. , Seymour, John F. , Woyach, Jennifer A. , Sharman, Jeff , Kay, Neil E , Rogers, Kerry A , Rhodes, Joanna , Eyre, Toby A , Sun, Clare , Cheah, Chan Yoon , Seymour, John F , Davids, Matthew S. , Roeker, Lindsey E. , Thompson, Meghan C , Goy, Andre Henri , Schuster, Stephen J. , Tam, Constantine S. , O’Brien, Susan , Shadman, Mazyar , Jain, Nitin

Mayo Clinic

Clinical Cancer Research | November 17, 2021 | Volume: 28 | Issue: 4 | Pages: 603-608

10.1158/1078-0432.ccr-21-1237 | PMID 34789482 Get It

Abstract The management of chronic lymphocytic leukemia (CLL) has undergone unprecedented changes over the last decade. Modern targeted therapies are incorporated into clinical practice. Unfortunately, patients have begun to develop resistance or intolerance to multiple classes. Symptomatic patients previously treated with a BTK inhibitor (BTKi) and venetoclax represent a new and rapidly growing unmet need in CLL. Here, we define unmet needs in a modern treatment context. We also critically review the literature for PI3K inhibitors and chemoimmunotherapy and lack of data to support their utility following BTKis and venetoclax. Finally, we suggest opportunities to ensure the continued innovation for patients with CLL.
ARMADA: Assessing reliable measurement in Alzheimer’s disease and cognitive aging project methods
Weıntraub, Sandra , Karpouzian‐Rogers, Tatiana , Peipert, John Devin , Nowinski, Cindy J. , Slotkin, Jerry , Wortman, Katy, Ho, Emily , Rogalskı, Emily , Carlsson, Cynthia M. , Lucas, John A. , Salmon, David P. , Snitz, Beth E. , Riley, Michaela , Eldes, Fatima, Ustsinovich, Vitali , Lucas, John, Peipert, John Devin , Giordani, Bruno , Goldstein, Felicia C. , Manly, Jennifer J. , Rentz, Dorene M. , Dodge, Hiroko Hayama , Gershon, Richard C

Mayo Clinic

Alzheimer's & Dementia | November 17, 2021 | Volume: 18 | Issue: 8 | Pages: 1449-1460

10.1002/alz.12497 | PMID 34786833 Get It

AbstractIntroductionEarly detection of cognitive decline in older adults is a public health priority. Advancing Reliable Measurement in Alzheimer's Disease and Cognitive Aging (ARMADA), a multisite study, is validating cognition, emotion, motor, and sensory modules of the National Institutes of Health Toolbox for Assessment of Neurological and Behavioral Function (NIHTB) in the aging spectrum from cognitively normal to dementia of the Alzheimer's type (DAT).MethodsParticipants 65 to 85 years old, in demographic groups racially proportional to the general US population, are recruited in one of three groups to validate the NIHTB: cognitively normal, amnestic mild cognitive impairment (aMCI), or mild DAT. Additional special emphasis cohorts include (1) Blacks in the three clinical groups; (2) Spanish‐speakers in the three clinical groups; (3) cognitively normal, population‐proportional, over age 85.DiscussionLongitudinal study will determine whether NIHTB can predict cognitive decline and is associated with Alzheimer's disease biomarkers. Here, we detail the methods for the ARMADA study.
Empowering Women as Leaders in Pediatric Anesthesiology: Methodology, Lessons, and Early Outcomes of a National Initiative
Schwartz, Jamie McElrath , Markowitz, Scott D. , Yanofsky, Samuel D., Tackett, Sean , Berenstain, Laura K. , Schwartz, Lawrence , Flick, Randall P., Heitmiller, Eugenie S., Fiadjoe, John E. , Lee, Helen H. , Honkanen, Anita , Malviya, Shobha , Cladis, Franklyn P. , Lee, Jennifer K. , Flick, Randall, Deutsch, Nina

Mayo Clinic

Anesthesia & Analgesia | November 16, 2021 | Volume: 133 | Issue: 6 | Pages: 1497-1509

10.1213/ane.0000000000005740 | PMID 34517375 Get It

Research has shown that women have leadership ability equal to or better than that of their male counterparts, yet proportionally fewer women than men achieve leadership positions and promotion in medicine. The Women’s Empowerment and Leadership Initiative (WELI) was founded within the Society for Pediatric Anesthesia (SPA) in 2018 as a multidimensional program to help address the significant career development, leadership, and promotion gender gap between men and women in anesthesiology. Herein, we describe WELI’s development and implementation with an early assessment of effectiveness at 2 years. Members received an anonymous, voluntary survey by e-mail to assess whether they believed WELI was beneficial in several broad domains: career development, networking, project implementation and completion, goal setting, mentorship, well-being, and promotion and leadership. The response rate was 60.5% (92 of 152). The majority ranked several aspects of WELI to be very or extremely valuable, including the protégé-advisor dyads, workshops, nomination to join WELI, and virtual facilitated networking. For most members, WELI helped to improve optimism about their professional future. Most also reported that WELI somewhat or absolutely contributed to project improvement or completion, finding new collaborators, and obtaining invitations to be visiting speakers. Among those who applied for promotion or leadership positions, 51% found WELI to be somewhat or absolutely valuable to their application process, and 42% found the same in applying for leadership positions. Qualitative analysis of free-text survey responses identified 5 main themes: (1) feelings of empowerment and confidence, (2) acquisition of new skills in mentoring, coaching, career development, and project implementation, (3) clarification and focus on goal setting, (4) creating meaningful connections through networking, and (5) challenges from coronavirus disease 2019 (COVID-19) and the inability to sustain the advisor-protégé connection. We conclude that after 2 years, the WELI program has successfully supported career development for the majority of protégés and advisors. Continued assessment of whether WELI can meaningfully contribute to attainment of promotion and leadership positions will require study across a longer period. WELI could serve as a programmatic example to support women’s career development in other subspecialties.
Targeted Detection of SARS-CoV-2 Nucleocapsid Sequence Variants by Mass Spectrometric Analysis of Tryptic Peptides
Maus, Anthony , Renuse, Santosh , Kemp, Jennifer, Madugundu, Anil K. , Vanderboom, Patrick M. , Blommel, Joseph H. , Jerde, Calvin R. , Dasari, Surendra , Kipp, Benjamin R. , Grebe, Stefan K. , Pandey, Akhilesh , Blommel, Joseph, Jerde, Calvin, Pandey, Akhilesh , Pandey, Akhilesh , Maus, Anthony D , Singh, Ravinder J.

Mayo Clinic

Journal of Proteome Research | November 15, 2021 | Volume: 21 | Issue: 1 | Pages: 142-150

10.1021/acs.jproteome.1c00613 | PMID 34779632 Get It

Large cell calcifying Sertoli cell tumour: a contemporary multi‐institutional case series highlighting the diagnostic utility of PRKAR1A immunohistochemistry
Anderson, William J. , Gordetsky, Jennifer , Idrees, Muhammad T. , Al‐Obaidy, Khaleel I. , Kao, Chia‐Sui , Cornejo, Kristine M. , Wobker, Sara E. , Cheville, John C. , Vargas, Sara O. , Fletcher, Christopher D.�M. , Hirsch, Michelle S. , Gordetsky, Jennifer B , Acosta, Andrés M , Al-Obaidy, Khaleel , Acosta, Andrés

Mayo Clinic

Histopathology | November 15, 2021 | Volume: 80 | Issue: 4 | Pages: 677-685

10.1111/his.14599 | PMID 34780072 Get It

AimsLarge cell calcifying Sertoli cell tumour (LCCSCT) is a rare testicular sex cord‐stromal tumour that primarily affects young patients and is associated with Carney complex. We sought to characterise the clinicopathological features of a series of LCCSCT and evaluate the diagnostic utility of PRKAR1A immunohistochemistry (IHC).Methods and resultsThe LCCSCT cohort (n = 15) had a median age of 16 years (range = 2–30 years). Four patients were known to have Carney complex. PRKAR1A IHC was performed in each case. For comparison, PRKAR1A IHC was also assessed in other sex cord‐stromal tumours, including Sertoli cell tumour, not otherwise specified (SCT, NOS; n = 10), intratubular large cell hyalinising Sertoli cell tumour (n = 1) and Leydig cell tumour (n = 23). Loss of cytoplasmic PRKAR1A expression was observed in all but one LCCSCT (14 of 15; 93%). PRKAR1A expression was retained in all SCTs, NOS (10 of 10; 100%), the majority of Leydig cell tumours (22 of 23; 96%) and an intratubular large cell hyalinising Sertoli cell tumour (1 of 1; 100%). One Leydig cell tumour showed equivocal staining (multifocal weak expression).ConclusionsOverall, PRKAR1A loss is both sensitive (93%) and highly specific (97%) for the diagnosis of LCCSCT. PRKAR1A loss may aid its diagnosis, particularly in sporadic cases and those that are the first presentation of Carney complex.
Oral Contraceptive Pills Are an Effective Method of Preventing Pregnancy in Women With Crohn’s Disease
Daoud, Nader , Ghoz, Hassan , Cannon, Rachel , Farraye, Jennifer , Picco, Michael F., Kane, Sunanda V. , Kochhar, Gursimran , Farraye, Francis A. , Daoud, Nader D , Farraye, Francis A , Woodhams, Elisabeth J.

Mayo Clinic

Crohn's & Colitis 360 | November 12, 2021 | Volume: 4 | Issue: 1 | Pages: No page available

10.1093/crocol/otab078 | PMID 36777546 Get It

Abstract Background Oral contraceptive pill (OCP) use in the general population is associated with a failure rate as low as 0.3% with perfect use but as high as 9% with typical use. Women with Crohn’s disease (CD) may have malabsorption in the setting of small bowel disease or resection, which could affect absorption of OCPs. Our aim was to determine the incidence of pregnancy in women with CD on OCPs. Methods This is a retrospective study assessing the incidence rate of OCP failure in females between 18 and 45 years of age seen at the Mayo Clinic with a diagnosis of CD and provided a prescription for OCPs, between 2016 and 2020. Failure was defined as clear documentation of becoming pregnant while using OCPs or having an active prescription of OCP at the time of conception. Results A total of 818 female patients with CD between 18 and 45 years of age with a prescription for an OCP were included in our study. Sixty-six patients (8%) conceived in this cohort. Of the 66 patients who became pregnant, 57 stopped the OCP before conceiving, 5 were excluded due to lack of data, and 4 women had active oral contraceptive prescriptions when they became pregnant (pregnancy rate of 0.5%). Conclusions In female patients with CD who are using OCPs for contraception, we found a low rate of pregnancy (0.5%) similar to the rate of pregnancy with perfect use of OCPs in the general population. OCPs are an effective method of birth control in women with CD.
Consensus practice guidelines on interventions for cervical spine (facet) joint pain from a multispecialty international working group
Hurley, Robert W. , Adams, Meredith C B , Barad, Meredith , Bhaskar, Arun , Bhatia, Anuj , Deer, Timothy R. , Hah, Jennifer M. , Hooten, W. Michael , Lee, David Wonhee, McCormick, Zachary L. , Schneider, Byron J. , Eerd, Maarten van , Zundert, Jan Van , Wallace, Mark S. , Wilson, Sara M, Zhao, Zirong , Chadwick, Andrea , Deer, Tim , Hooten, W Michael , Moon, Jee Youn , Narouze, Samer , Cohen, Steven P , van Zundert, Jan , Hurley, Robert W , Barad, Meredith J , Hah, Jennifer M , Bhatia, Anuj , Kissoon, Narayan , Narouze, Samer , Provenzano, David , Cohen, Steven P.

Mayo Clinic

Regional Anesthesia & Pain Medicine | November 11, 2021 | Volume: 47 | Issue: 1 | Pages: 3-59

10.1136/rapm-2021-103031 | PMID 34764220 Get It

Background The past two decades have witnessed a surge in the use of cervical spine joint procedures including joint injections, nerve blocks and radiofrequency ablation to treat chronic neck pain, yet many aspects of the procedures remain controversial. Methods In August 2020, the American Society of Regional Anesthesia and Pain Medicine and the American Academy of Pain Medicine approved and charged the Cervical Joint Working Group to develop neck pain guidelines. Eighteen stakeholder societies were identified, and formal request-for-participation and member nomination letters were sent to those organizations. Participating entities selected panel members and an ad hoc steering committee selected preliminary questions, which were then revised by the full committee. Each question was assigned to a module composed of 4–5 members, who worked with the Subcommittee Lead and the Committee Chairs on preliminary versions, which were sent to the full committee after revisions. We used a modified Delphi method whereby the questions were sent to the committee en bloc and comments were returned in a non-blinded fashion to the Chairs, who incorporated the comments and sent out revised versions until consensus was reached. Before commencing, it was agreed that a recommendation would be noted with >50% agreement among committee members, but a consensus recommendation would require ≥75% agreement. Results Twenty questions were selected, with 100% consensus achieved in committee on 17 topics. Among participating organizations, 14 of 15 that voted approved or supported the guidelines en bloc, with 14 questions being approved with no dissensions or abstentions. Specific questions addressed included the value of clinical presentation and imaging in selecting patients for procedures, whether conservative treatment should be used before injections, whether imaging is necessary for blocks, diagnostic and prognostic value of medial branch blocks and intra-articular joint injections, the effects of sedation and injectate volume on validity, whether facet blocks have therapeutic value, what the ideal cut-off value is for designating a block as positive, how many blocks should be performed before radiofrequency ablation, the orientation of electrodes, whether larger lesions translate into higher success rates, whether stimulation should be used before radiofrequency ablation, how best to mitigate complication risks, if different standards should be applied to clinical practice and trials, and the indications for repeating radiofrequency ablation. Conclusions Cervical medial branch radiofrequency ablation may provide benefit to well-selected individuals, with medial branch blocks being more predictive than intra-articular injections. More stringent selection criteria are likely to improve denervation outcomes, but at the expense of false-negatives (ie, lower overall success rate). Clinical trials should be tailored based on objectives, and selection criteria for some may be more stringent than what is ideal in clinical practice.